Mentixa

Memantine Hydrochloride, the active ingredient in Mentixa, is a NMDA receptor antagonist presented as an oral formulation for oral use. It is used to treat moderate to severe Alzheimer’s disease in adults. GNH USA supplies Mentixa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mentixa is an NMDA receptor antagonist indicated for the treatment of Alzheimer’s disease and related cognitive decline. - Moderate Alzheimer’s disease: helps maintain cognition and daily functioning. - Severe Alzheimer’s disease: reduces progression of functional decline. - Alzheimer’s disease combined therapy: used together with cholinesterase inhibitors to enhance symptomatic benefit.

Adverse reactions to Memantine may vary in frequency and severity.

Common Side Effects: - Dizziness: transient light‑headedness, especially after dose initiation. - Headache: mild to moderate intensity, often resolves with continued therapy. - Constipation: reduced bowel movements, manageable with diet or laxatives. - Insomnia: difficulty falling or staying asleep, may improve with dose timing adjustments.

Serious or Rare Side Effects: - Seizures: new‑onset convulsions requiring immediate medical attention. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or jaundice, monitor liver function tests.

When prescribing Memantine, clinicians should consider several safety factors. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - History of seizures: monitor closely for increased seizure activity. - Concurrent NMDA antagonists: avoid co‑administration to reduce additive CNS effects. - Pregnancy: risk category unknown; use only if potential benefit justifies potential risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine can interact with other medicines, necessitating careful management.

Major Interactions (Avoid): - Amantadine: additive central nervous system effects may increase confusion. - Ketamine: combined NMDA blockade can lead to excessive sedation or neurotoxicity. - High‑dose NSAIDs: may raise the risk of peripheral edema.

Moderate Interactions (Monitor Closely): - Anticholinesterase inhibitors: may diminish therapeutic benefit of Memantine. - Diuretics: can affect blood pressure and electrolyte balance. - Alcohol: may intensify dizziness and sedation.